Wood Sherri, Feng Jiane, Chung Jooho, Radojcic Vedran, Sandy-Sloat Ashley R, Friedman Ann, Shelton Amy, Yan Minhong, Siebel Christian W, Bishop D Keith, Maillard Ivan
Department of Surgery, University of Michigan, Ann Arbor, MI 48109;
Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109; Graduate Program in Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI; Medical Scientist Training Program, University of Michigan, Ann Arbor, MI;
J Immunol. 2015 Mar 15;194(6):2899-908. doi: 10.4049/jimmunol.1402034. Epub 2015 Feb 16.
Rejection remains a major clinical challenge limiting allograft survival after solid organ transplantation. Both cellular and humoral immunity contribute to this complication, with increased recognition of Ab-mediated damage during acute and chronic rejection. Using a mouse model of MHC-mismatched heart transplantation, we report markedly protective effects of Notch inhibition, dampening both T cell and Ab-driven rejection. T cell-specific pan-Notch blockade prolonged heart allograft survival and decreased IFN-γ and IL-4 production by alloreactive T cells, especially when combined with depletion of recipient CD8(+) T cells. These effects were associated with decreased infiltration by conventional T cells and an increased proportion of regulatory T cells in the graft. Transient administration of neutralizing Abs specific for delta-like (Dll)1/4 Notch ligands in the peritransplant period led to prolonged acceptance of allogeneic hearts, with superior outcome over Notch inhibition only in T cells. Systemic Dll1/4 inhibition decreased T cell cytokines and graft infiltration, germinal center B cell and plasmablast numbers, as well as production of donor-specific alloantibodies and complement deposition in the transplanted hearts. Dll1 or Dll4 inhibition alone provided partial protection. Thus, pathogenic signals delivered by Dll1/4 Notch ligands early after transplantation promote organ rejection through several complementary mechanisms. Transient interruption of these signals represents an attractive new therapeutic strategy to enhance long-term allograft survival.
排斥反应仍然是限制实体器官移植后同种异体移植物存活的主要临床挑战。细胞免疫和体液免疫均会导致这一并发症,在急性和慢性排斥反应中,抗体介导的损伤越来越受到关注。利用 MHC 不匹配的心脏移植小鼠模型,我们报告了 Notch 抑制的显著保护作用,可抑制 T 细胞和抗体介导的排斥反应。T 细胞特异性泛 Notch 阻断延长了心脏同种异体移植物的存活时间,并降低了同种反应性 T 细胞产生的 IFN-γ 和 IL-4,特别是与受体 CD8(+) T 细胞耗竭联合使用时。这些作用与传统 T 细胞浸润减少以及移植物中调节性 T 细胞比例增加有关。在移植期给予针对 delta-like(Dll)1/4 Notch 配体的中和抗体可导致同种异体心脏的长期存活,其结果优于仅抑制 T 细胞中的 Notch。全身性 Dll1/4 抑制降低了 T 细胞细胞因子和移植物浸润、生发中心 B 细胞和浆母细胞数量,以及供体特异性同种抗体的产生和移植心脏中的补体沉积。单独抑制 Dll1 或 Dll4 提供了部分保护。因此,移植后早期 Dll1/4 Notch 配体传递的致病信号通过多种互补机制促进器官排斥。短暂中断这些信号代表了一种有吸引力的新治疗策略,可提高同种异体移植物的长期存活率。